Poseida Therapeutics (PSTX) Q3 2024 earnings summary

Executive summary

• Achieved net income of $20.2 million for Q3 2024, reversing a net loss of $31.8 million in Q3 2023, driven by significant collaboration revenue growth and expanded partnerships with Roche and Astellas.

• Collaboration revenue surged to $71.7 million in Q3 2024, primarily from Roche and Astellas agreements, with milestone recognition and increased reimbursed R&D expenses.

• Generated $130 million in milestone and upfront payments in 2024, remaining cash flow positive for the first nine months.

• Presented positive interim Phase 1 results for P-BCMA-ALLO1, showing a 91% overall response rate in multiple myeloma patients.

• Ended Q3 2024 with $230.9 million in cash, cash equivalents, and short-term investments, expected to fund operations into early 2026.

Financial highlights

• Q3 2024 collaboration revenue: $71.7 million, up from $9.4 million in Q3 2023; nine-month revenue: $125.9 million, up from $39.7 million year-over-year.

• Q3 2024 net income: $20.2 million; nine-month net loss: $35.4 million, improved from $98.1 million net loss in the prior year period.

• Q3 2024 R&D expenses: $41.9 million; nine-month R&D expenses: $130.4 million, up $15.7 million year-over-year.

• Q3 2024 general and administrative expenses: $10.1 million, up $2.0 million year-over-year; nine-month G&A: $32.1 million, up $3.5 million.

• Cash provided by operations for the nine months ended September 30, 2024: $13.7 million, compared to $63.4 million used in the prior year period.

Outlook and guidance

• Cash, cash equivalents, and short-term investments of $230.9 million as of September 30, 2024, expected to fund operations into early 2026.

• Anticipates continued net losses and negative cash flows from operations for the next several years as R&D activities expand.

• Expects increased expenses as clinical and preclinical programs advance and headcount grows.

• Ongoing collaborations with Roche and Astellas may yield additional milestone payments and extend the cash runway.

• Further updates on the CAR-T pipeline expected, including presentations at major conferences in late 2024.